A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

Trial Profile

A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Sep 2018

At a glance

  • Drugs Bupropion/dextromethorphan (Primary) ; Bupropion
  • Indications Agitation
  • Focus Therapeutic Use
  • Acronyms ADvance; ADVANCE-1
  • Sponsors Axsome Therapeutics
  • Most Recent Events

    • 19 Sep 2018 According to an Axsome Therapeutics media release, the company plans to provide an interim analysis for futility of this study in the fourth quarter of 2018..
    • 17 Jul 2018 According to an Axsome Therapeutics media release, the current status of this study will be presented at the 2018 Alzheimer's Association International Conference (AAIC) on July 2018.
    • 03 May 2018 According to an Axsome Therapeutics media release, the current status of this study will be presented at the 2018 Annual Meeting of the American Psychiatric Association on May 8, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top